OUR MISSION

Programmable gene silencing to transform advanced therapies

THE SCIENCE

WE ARE

Laverock Therapeutics

Laverock Therapeutics is a gene silencing company with a uniquely powerful technology which harnesses the cell's natural gene regulatory mechanisms to develop a new generation of more effective, safer and accessible programmable advanced therapies to tackle major diseases.

FIND OUT MORE

Programmable, tunable, stable and specific

Laverock’s truly innovative technology harnesses the power of reprogramming the cell’s own gene control systems to develop advanced therapies that respond to specific cellular conditions and/or disease states. 


The approach is based on the re-purposing of naturally-occurring microRNAs (miRNAs) to conditionally silence genes in a way which is programmable, tunable, stable and specific: the right genes, in the right cell, at the right level, at the right time.

LEARN MORE

Therapeutics

Laverock is applying its technology to areas where advanced therapies have the potential to transform treatment for serious diseases both through its own drug development programmes tackling regenerative medicine and oncology, and through partnerships. 



FIND OUT MORE

CHECK OUT OUR

Latest News

By Juliette Craggs 26 Sep, 2024
Programmable, tunable, stable and specific gene silencing has been demonstrated across multiple target genes and multiple cell types PoC achieved with concomitant silencing of more than one gene Industrialisation of platform processes delivering significant increase in throughput Strategic in-house focus on development of pipeline of programmable advanced therapies in oncology and genetic disease Potential additional application to multiple high impact therapeutic areas through partnering including, hypoimmunogenicity/type 1 diabetes, inflammatory diseases and fibrosis
05 Sep, 2024
Stevenage, UK, 5 September 2024 - Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces its conference attendance programme for the remainder of 2024. Forthcoming events include: ISCT Europe Regional Meeting , 4 – 6 September in Gothenburg - speaking Healthtech Innovation Day , 17 – 18 September in Paris - speaking, investor meetings Sachs Biotech in Europe Forum , 25 – 26 September in Basel - speaking, investor meetings and partnering Chardan Genetics Medicines Conference , 30 September – 1 October in New York - speaking, investor meetings and partnering ARM Meeting on the Mesa , 7 – 9 October in Phoenix, AZ – speaking, investor meetings and partnering TechBio UK 2024 , 16 October in London - panellist ESGCT Congress , 22 – 25 October in Rome - scientific presentations BioEurope , 4 – 6 November in Stockholm - investor meetings and partnering Cell 2024 , 6 – 8 November in London - speaking, session chair, panellist David Venables, CEO of Laverock, said: “We are excited to be showcasing recent advances in our technology at a number of key investor, scientific and partnering events. Over the course of 2024, Laverock has further validated its platform’s ability to silence genes in a programmable, tunable, stable and highly specific manner across multiple target genes and cell types. We have also broadened the platform’s potential by demonstrating the ability to silence more than one gene concomitantly. These developments further expand the range of potential applications for Laverock’s technology.” To arrange meetings with the Laverock leadership team at any of these events, please contact: contact@laverocktx.com ENDS For further information please contact: Laverock Therapeutics: E: contact@laverocktx.com Media Enquiries : Charles Consultants Sue Charles – Sue@charles-consultants.com +44 (0)7968 726585 Chris Gardner – Chris@CGComms.onmicrosoft.com +44 (0)7956 031077 About Laverock Therapeutics Laverock Therapeutics is a gene-silencing company with a uniquely powerful technology which harnesses the cell’s natural gene regulatory mechanisms to develop a new generation of programmable advanced therapies to tackle major diseases. Laverock’s truly innovative technology re-directs naturally-occurring micro RNAs (miRNAs) to conditionally silence genes in a way which is programmable, tunable, stable and specific. This opens a path to more effective, safer and accessible advanced therapies. Laverock is applying its technology through its own pipeline – targeting regenerative medicine and oncology – and through partnerships. Laverock has a highly experienced leadership team with proven track records in biotechnology, pharma and academia and an exceptionally strong Board. Laverock completed a £13.5m seed round in September 2023. Its high-calibre investors include Calculus Capital, Eli Lilly and Company, Mercia Ventures, Maven Capital Partners, Eos, UK Innovation & Science Seed Fund and Tekfen Ventures. For more information, please visit www.laverocktx.com and follow us on LinkedIn .
By Juliette Craggs 26 Mar, 2024
Stevenage, UK, 26 March 2024 - Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces the appointment of Ali Elsley as Finance Director.  Ali has extensive experience in the biotechnology and pharma sector working with both private and public companies. She joins from Acacia Pharma Group plc, an early commercial-stage listed pharma company, where she was Group Financial Controller and Company Secretary and focused on equity fundraising, M&A activity and all aspects of financial operations. Prior to this, she spent 10 years as an auditor with PwC LLP in Cambridge, with a focus on early-stage biotech and pharma companies, together with advisory IPO work. She is a fellow of the Institute of Chartered Accountants in England and Wales and holds a degree in Archaeology and Anthropology from the University of Cambridge. In addition to Ali’s appointment, Laverock has significantly grown its team to 24 people, representing growth of 50% over the past year, and expanded its R&D facilities in the Stevenage Bioscience Catalyst as it continues to build its capabilities following its £13.5m expanded seed round announced in September last year, the second highest seed investment by a UK company in 2023. David Venables, CEO of Laverock, said: “Ali has an exceptional track record working with innovative biotechnology and pharma companies. I very much look forward to working closely with her and the rest of our fast-growing team as we continue to apply our uniquely powerful gene-silencing technology to the development of a new generation of programmable advanced therapies to tackle major diseases.” Ali Elsley, FD of Laverock, said: “Laverock’s technology has the potential to create a step-change in advanced therapies and I have been hugely impressed with the pace of progress since joining the company. The management team and Board are exceptionally strong, and I believe we have a very solid foundation from which to deliver on the promise.” ENDS For further information please contact: Laverock Therapeutics: E: contact@laverocktx.com Media Enquiries : Charles Consultants Sue Charles – Sue@charles-consultants.com +44 (0)7968 726585 Chris Gardner – Chris@CGComms.onmicrosoft.com +44 (0)7956 031077 About Laverock Therapeutics Laverock Therapeutics is a gene-silencing company with a uniquely powerful technology which harnesses the cell’s natural gene regulatory mechanisms to develop a new generation of programmable advanced therapies to tackle major diseases. Laverock’s truly innovative technology re-directs naturally-occurring micro RNAs (miRNAs) to conditionally silence genes in a way which is programmable, tunable, stable and specific. This opens a path to more effective, safer and accessible advanced therapies. Laverock is applying its technology through its own pipeline – targeting regenerative medicine and oncology – and through partnerships. Laverock has a highly experienced leadership team with proven track records in biotechnology, pharma and academia and an exceptionally strong Board. Laverock completed a £13.5m seed round in September 2023. Its high-calibre investors include Calculus Capital, Eli Lilly and Company, Mercia Ventures, Maven Capital Partners, Eos, UK Innovation & Science Seed Fund and Tekfen Ventures. For more information, please visit www.laverocktx.com and follow us on LinkedIn .
Share by: